Search

Your search keyword '"Toshiaki, Ohkuma"' showing total 4 results
Start Over Author "Toshiaki, Ohkuma" Publisher ovid technologies (wolters kluwer health)
4 results on '"Toshiaki, Ohkuma"'

1. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program

Author

Gregory R. Fulcher, Qiang Li, David R. Matthews, Hiddo J.L. Heerspink, Bruce Neal, William Canovatchel, Tadashi Toyama, Dick de Zeeuw, Vlado Perkovic, Kenneth W. Mahaffey, Toshiaki Ohkuma, Megumi Oshima, Groningen Kidney Center (GKC), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Subjects
Male, medicine.medical_specialty, eGFR decline, Urology, Hemodynamics, Type 2 diabetes, 030204 cardiovascular system & hematology, Placebo, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Clinical Research, Humans, Medicine, 030212 general & internal medicine, Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Aged, Creatinine, business.industry, 1103 Clinical Sciences, General Medicine, Urology & Nephrology, Middle Aged, medicine.disease, Confidence interval, Survival Rate, Clinical trial, Diabetes Mellitus, Type 2, chemistry, Nephrology, Relative risk, Kidney Failure, Chronic, Female, business, SGLT2 inhibitors, Glomerular Filtration Rate, medicine.drug
Abstract

BACKGROUND: Traditionally, clinical trials evaluating effects of a new therapy with creatinine-based renal end points use doubling of serum creatinine (equivalent to a 57% eGFR reduction), requiring large sample sizes.METHODS: To assess whether eGFR declines RESULTS: Among the 10,142 participants, 93 (0.9%), 161 (1.6%), 352 (3.5%), and 800 (7.9%) participants recorded renal outcomes on the basis of 57%, 50%, 40%, or 30% eGFR reduction, respectively, during a mean follow-up of 188 weeks. Compared with a 57% eGFR reduction (risk ratio [RR], 0.51; 95% confidence interval [95% CI], 0.34 to 0.77), the effect sizes were progressively attenuated when using 50% (RR, 0.61; 95% CI, 0.45 to 0.83), 40% (RR, 0.70; 95% CI, 0.57 to 0.86), or 30% (RR, 0.81; 95% CI, 0.71 to 0.93) eGFR reductions. In analyses that controlled for the acute hemodynamic fall in eGFR, effect sizes were comparable, regardless of whether a 57%, 50%, 40%, or 30% eGFR reduction was used. Estimated sample sizes for studies on the basis of lesser eGFR reductions were much reduced by controlling for this early hemodynamic effect.CONCLUSIONS: Declines in eGFR CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: CANagliflozin cardioVascular Assessment Study (CANVAS), NCT01032629 and CANVAS-R, NCT01989754.

Published
2020

2. Steno-Stiffness Approach for Cardiovascular Disease Risk Assessment in Primary Prevention

Author

Mitsuru Ohishi, Tetsuo Shoji, Toshiharu Ninomiya, Toshiaki Ohkuma, Chisa Mastumoto, Yoshikuni Kita, Toyoshi Inoguchi, Yasutaka Maeda, Hirotaka Watada, Masanori Munakata, Michinari Nakamura, Takayoshi Ohkubo, Motoyuki Nakamura, Akira Yamashina, Kazuomi Kario, Norihisa Ito, Hirofumi Tomiyama, Katsuhiko Kohara, Satoshi Hoshide, Yasuharu Tabara, Victor Aboyans, Charalambos Vlachopoulos, Tohoku University [Sendai], Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), and Grelier, Elisabeth

Subjects
medicine.medical_specialty, business.industry, MEDLINE, Stiffness, 030204 cardiovascular system & hematology, Risk Assessment, 3. Good health, Primary Prevention, 03 medical and health sciences, Vascular Stiffness, 0302 clinical medicine, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cardiovascular Diseases, Risk Factors, Primary prevention, Internal Medicine, medicine, Disease risk, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, 030212 general & internal medicine, medicine.symptom, Intensive care medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

3. Simultaneously Measured Interarm Blood Pressure Difference and Stroke

Author

Toshiharu Ninomiya, Hirofumi Tomiyama, Yasutaka Maeda, Katsuhiko Kohara, Motoyuki Nakamura, Toshiaki Ohkuma, Hirotaka Watada, Mitsuru Ohishi, Norihisa Ito, Akira Yamashina, Kazuomi Kario, Tetsuo Shoji, Masanori Munakata, Chisa Mastumoto, Michinari Nakamura, Charalambos Vlachopoulos, Yoshikuni Kita, Satoshi Hoshide, Yasuharu Tabara, Takayoshi Ohkubo, and Toyoshi Inoguchi

Subjects
medicine.medical_specialty, business.industry, Individual participant data, Blood Pressure, Blood Pressure Determination, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Blood pressure, Physical medicine and rehabilitation, medicine.anatomical_structure, Risk Factors, Meta-analysis, Primary prevention, Hypertension, Internal Medicine, medicine, Humans, Ankle Brachial Index, 030212 general & internal medicine, Ankle, Risk assessment, business, Stroke
Abstract

We conducted individual participant data meta-analysis to examine the validity of interarm blood pressure difference in simultaneous measurement as a marker to identify subjects with ankle-brachial pressure index 5 mm Hg as being associated with a significant odds ratio for the presence of ankle-brachial pressure index P 15 mm Hg was associated with a significant Cox stratified adjusted hazard ratio for subsequent stroke (hazard ratio, 2.42; 95% confidence interval, 1.27–4.60; P

Published
2018

4. Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease

Author

Toshiaki Ohkuma, Toshiharu Ninomiya, Hirofumi Tomiyama, Kazuomi Kario, Satoshi Hoshide, Yoshikuni Kita, Toyoshi Inoguchi, Yasutaka Maeda, Katsuhiko Kohara, Yasuharu Tabara, Motoyuki Nakamura, Takayoshi Ohkubo, Hirotaka Watada, Masanori Munakata, Mitsuru Ohishi, Norihisa Ito, Michinari Nakamura, Tetsuo Shoji, Charalambos Vlachopoulos, Akira Yamashina, Masahide Nagano, Ogata Yukiyo, Tomoyuki Kabutoya, Kei Asayama, Naoyuki Takashima, Tanvir Turin Chowdhury, Kayo Mitsuki-Shinohara, and Takeshi Yamashita

Subjects
Male, medicine.medical_specialty, Brachial Artery, Pulse Wave Analysis, Disease, 030204 cardiovascular system & hematology, Risk Assessment, Cohort Studies, 03 medical and health sciences, Age Distribution, Vascular Stiffness, 0302 clinical medicine, Physical medicine and rehabilitation, Internal Medicine, medicine, Humans, Ankle Brachial Index, Prospective Studies, 030212 general & internal medicine, Sex Distribution, Prospective cohort study, Aged, Proportional Hazards Models, business.industry, Proportional hazards model, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Cardiovascular Diseases, Meta-analysis, Arterial stiffness, Female, Risk assessment, business, Cohort study
Abstract

An individual participant data meta-analysis was conducted in the data of 14 673 Japanese participants without a history of cardiovascular disease (CVD) to examine the association of the brachial-ankle pulse wave velocity (baPWV) with the risk of development of CVD. During the average 6.4-year follow-up period, 687 participants died and 735 developed cardiovascular events. A higher baPWV was significantly associated with a higher risk of CVD, even after adjustments for conventional risk factors ( P for trend P P P P

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results